Category: Crohn's

Ocera Therapeutics, Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary compounds to treat gastrointestinal and liver diseases announced today that it has completed the patient enrollment of its Phase 3 study in fistulizing Crohn’s disease.

Ocera Therapeutics, Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary compounds to treat gastrointestinal and liver diseases announced today that it has completed the patient enrollment of its Phase 3 study in fistulizing Crohn’s disease.

Light exercise such as walking may be helpful for some people with
the digestive disorder Crohn’s disease, a study has found.

Among women with Crohn’s disease, having active disease during
pregnancy raises the risk of preterm birth, according to a study.
Crohn’s disease is a debilitating inflammation in the digestive
tract that often affects women of childbearing age. The cause of
the disease remains unclear.

Research hints that children who don’t get the right balance of
fatty acids, vegetables and fruits may be at increased risk of
developing Crohn’s disease — a debilitating inflammation in the
digestive tract, the cause of which remains unclear.

A patient with inflammatory bowel disease is four times as likely to die from Clostridium difficile infection compared to a person who does not have the disease, according to an article published ahead of print in the journal Gut (BMJ).The number of new cases of C difficile infection has been steadily rising over the last few years. C difficile is a major cause of diarrhea among inpatients, say the writers.

A change to the Pharmaceutical Benefits Scheme (PBS) from 1 October 2007 will provide subsidised access to adults and children of Remicade® (infliximab) for the treatment of Crohn’s disease.Crohn’s disease is an inflammatory disorder of the gastrointestinal tract. It can have a profound impact on professional, family and social life. Those with active Crohn’s disease experience chronic abdominal pain, diarrhoea and bowel movements containing blood.

Contact with farm environments in infancy might decrease the risk of juvenile Crohn’s disease and ulcerative colitis. That’s according to a study conducted in Germany entitled, “Contact With Farm Animals in Early Life and Juvenile Inflammatory Bowel Disease: A Case-Control Study.” Parents of children (ages 6 to 18) from 13 hospitals received a questionnaire regarding consumption of raw milk, contact with farm animals or pets, age of contact, and presence of respiratory allergies.

Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced today that the Gastrointestinal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 12 in favor to 3 opposed, with 2 abstaining, to recommend approval of TYSABRI® (natalizumab) as a treatment for moderate-to-severe Crohn’s disease in patients who have failed or cannot tolerate available therapies.

Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced today that they have been informed by the European Medicines Agency (EMEA) that the Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion on the marketing application for the use of natalizumab in patients with Crohn’s disease. In accordance with European regulations, Elan and Biogen Idec plan to apply for a re-examination of the negative opinion through the appeal procedure.